Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2004AIDSOpen Access

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMichela ViolinUniversity of MilanACAlessandro Cozzi‐LepriThe George Institute for Global HealthRVRossella VellecaUniversity of Milan

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Violin et al. (2004) studied this question.

synapsesocial.com/papers/6a895ce365c8981d3ff7c072https://doi.org/10.1097/00002030-200401230-00012
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy1999 · 287 citations
  2. 2Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 2151997 · 124 citations
  3. 3Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants1998 · 116 citations
  4. 4Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals2002 · 127 citations
  5. 5Drug Resistance Patterns, Genetic Subtypes, Clinical Features, and Risk Factors in Military Personnel with HIV-1 Seroconversion1999 · 104 citations